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Dose reductionBackground and purpose: A multi-center prospective randomized clinical trial has been performed inves-
tigating whether a reduction of the dose to the elective nodal sites in head and neck cancer delivered by
intensity modulated radiotherapy (IMRT) would result in a reduction of late side effects without compro-
mising tumor control.
Materials and methods: Two hundred patients were included. The prescription dose to the elective nodal
volumes was a normalized iso-effective dose in 2 Gy fractions (NID2Gy) of 50 Gy in the standard arm and
of 40 Gy in the experimental arm. Late toxicity was scored at 6, 12, 18 and 24 months using the RTOG
scoring system.
Results: We observed a trend toward less dysphagia at 6 months in the experimental arm, however this
was not confirmed after longitudinal analysis. Regarding moderate salivary gland toxicity we observed
lower incidence of salivary gland toxicity Pgrade 1, at 6 (p = 0.01) and 18 months (p = 0.03).
Results: After two years of follow up, we did not observe significant differences in estimated local fail-
ure rate (14.1% in the 40 Gy arm vs 14.4% in the 50 Gy arm), estimated regional failure rate (13.0% vs 5.5%
in the 40 and the 50 Gy arm respectively), estimated metastatic recurrence (13.4% vs 18.5% in the 40 and
the 50 Gy arm respectively), estimated disease-free survival (57.9% vs 65.3% in the 40 and the 50 Gy arm
respectively) nor estimated overall survival (72.0% vs 73.2% in the 40 and the 50 Gy arm respectively).
Conclusions: In our study population there was no statistically significant difference regarding survival
and estimated recurrence rates between both arms of this study. We found a trend toward less dysphagia
at 6 months (however not significant after longitudinal analysis) and found a significant reduction of any
salivary gland toxicity at 6 and 18 months in the 40 Gy arm.
 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2016) xxx–xxxRadiotherapy (RT) with curative intent for head and neck cancer
(HNC) results in a significant amount of side effects due to
unwanted doses in normal tissues surrounding the target volume
[1,2]. One of the most important late side effects limiting quality
of life is swallowing dysfunction (dysphagia).
Following the introduction of more aggressive treatment strate-
gies for HNC in the last decades, more attention has been
addressed to late dysphagia [3–5]. Both concurrent chemotherapyand accelerated fractionation have been identified as significant
predictive factors to develop dysphagia [3–5,6]. The dose delivered
to the pharyngeal constrictor muscles plays a crucial role in the
development of severe late dysphagia [7–11]. Our research group
demonstrated in a previous paper that a dose de-escalation to
the elective lymph nodes in HNC results in significantly less dose
to these functionally important structures and less severe dyspha-
gia at 3 months following treatment [12].
In this paper we report the results of a multi-center prospective
randomized clinical trial that investigated whether a reduction of
the dose to the elective nodal sites would result in a reduction of
late dysphagia without compromising regional control.oma; a
2 Dose de-escalation to the elective neck in head and neck cancerMaterial and methods
A prospective randomized multicenter non-inferiority phase III
study was set up between 6 centers. Inclusion criteria were previ-
ously untreated, histologically proven squamous cell carcinoma of
the oral cavity, oropharynx, hypopharynx, larynx or cervical lymph
node metastases of unknown primary cancer (CUP). Patient work-
up was done according to institutional guidelines. T1–T2N0 were
allowed, if prophylactic neck irradiation was performed. Patients
were older than 18 years with a Karnofsky performance status
P70%. The decision for primary (chemo-)RT with curative intent
had to be made after a multidisciplinary meeting at each partici-
pating center. Concurrent chemotherapy was allowed, as well as
pretreatment lymph node dissection. Local ethics committee
approval was obtained before start of the study and all patients
gave written informed consent. Patients were randomized to two
treatment arms (experimental arm A and standard arm B). A total
of 200 patients were included in the study (100 for each arm). To
minimize the influence of center-specific parameters randomiza-
tion was performed per center.
All macroscopically affected tumor sites were treated up to a
normalized iso-effective dose in 2 Gy fractions (NID2Gy) of
70 Gy. Fractionation schedule and total dose delivered to the pri-
mary tumor and affected lymph nodes were left to the discretion
of each individual center. An overview of the different fractionation
schedules and CTV-PTV margins can be found in the preliminary
analysis of this study [12]. For the elective nodal volumes, patients
randomized in arm A (experimental arm) were treated up to a
NID2Gy of 40 Gy. For arm B (control arm) the elective nodal vol-
umes were treated up to a NID2Gy of 50 Gy (Fig. 1) [12].
All patients were treated with IMRT using either an in-house
developed extension of the GRATIS-software by Sherouse coupled
to dose calculation using Pinnacle version 6.2b or the commercially
available treatment planning systems (Eclipse, Palo Alto;
Tomotherapy High-art, Madison) and delivered using 6 or 10
MV photons using either a step-and-shoot, a sliding window or
rotational technique. Patient set-up and position verification was
performed according to each center’s discretion.
Late toxicity was scored at 6, 12, 18 and 24 months using the
RTOG scoring system.Assessment of HPV status
Since HPV status was not considered in the first paper, this was
currently assessed [12]. For all patients with oropharyngeal
tumors, formalin-fixed, paraffin-embedded (FFPE) tissue was cen-
tralized (University Hospital of Leuven) for HPV-status determina-
tion. HPV testing was performed using a previously validated
algorithm using p16 immunohistochemistry (IHC) followed by
HPV-polymerase chain reaction (PCR) [13–15]. A tumor was
regarded as HPV related when both p16 IHC as well as HPV-PCR
were positive.Fig. 1. Consort diagram of the study. *Information of 1 participating center (7
patients) could not be retrieved before close-out date of this analysis, yielding 193
patients for analysis.
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405, BD Pharmigen) was used. Sections were scored as p16 positive
when clear p16 immunoreactivity was seen in at least 50% of cells
[14]. DNA was extracted from PPFE sections using the QIAamp DNA
FFPE Tissue kit. Concentration and purity where then defined with
spectrophotometry. HPV status was determined with a PCR reac-
tion using the GP5+/6+ primer set.Endpoints of the study
The primary endpoint of the study was the rate of dysphagia at
6 months of follow-up.
Secondary endpoints of the study were: local, regional and
distant control; recurrence and site of recurrence; overall,
disease-free and disease-specific survival; stiffness of the neck;
skin toxicity; salivary gland toxicity and mucosal integrity.General considerations of the statistical analysis
Assuming a 70% rate of late dysphagia Pgrade 1 will be
unacceptable and a 50% rate will be expected (a = 0.05, p = 0.8,
two-tailed test) the power calculation of the study resulted in
200 eligible patients (100 patients per arm).
All tests were 2-sided and assessed at a significance level of 5%.
Due to the exploratory nature of the study, no adjustments were
made to the significance level to account for multiple testing. All
analyses have been performed using SAS System for Windows
(version 9.4).Statistical analysis of the late toxicity endpoints
The following toxicity endpoints were assessed: dysphagia,
stiffness of the neck, skin toxicity, salivary gland toxicity and
mucosal integrity.
A chi-square test for trend was performed at each time-point to
assess whether there was a statistically significant difference
between the two randomized groups. Because these tests are sus-
ceptible to bias due to missing data, early withdrawals and/or early
mortality, a longitudinal analyses using Generalized Estimating
Equations (GEE) was also performed since it has been documented
that GEE models can provide unbiased estimates even in such cir-
cumstances if the condition of Missingness at Random (MAR)
holds. The above toxicity endpoints were analyzed using a GEE
proportional odds model with an independent correlation matrix
to account for the clustering of the data.
Primarily, the longitudinal proportional odds model includes a
factor for randomized treatment, visit and their interaction. The
inclusion of the interaction allows for the treatment effect to vary
between visits. The effect of randomized treatment was estimated
from the GEE model at each visit.
In addition, analyses were done for the probability of having
severe (Pgrade 3) and moderate (Pgrade 1) toxicity. Since these
are binary endpoints, the longitudinal analyses were done by
means of a GEE logistic regression model.Statistical analysis of outcome
Overall and disease-free survival was estimated using Kaplan–
Meier methodology. Differences between treatments were
assessed by means of a log-rank test.
Competing risk methodology was used for local, regional or dis-
tant failure, whereby death was considered to be a competing risk,
to take the fact into account that patients who died cannot have a
recurrence in the future. Event rates were estimated using cumula-
tive incidence functions (CIF) and comparisons were made using
Gray’s test.therapy to the elective neck in head and neck squamous cell carcinoma; a
ncol (2016), http://dx.doi.org/10.1016/j.radonc.2016.08.009
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In case of a regional recurrence, the recurrence was contoured
on the CT study and rigidly co-registrated with the initial pretreat-
ment CT study. Co-registration was done automatically using
Eclipse Treatment Planning system. If this was not accurate, man-
ual registration was performed. To determine the exact location of
recurrence the method described by Dawson et al. was used [13].
The recurrences were classified as 1) ‘‘in-field,” in which 95% or
more of the recurrence volume (Vrecur) was within the 95% iso-
dose; 2) ‘‘marginal,” in which 20% to 95% of Vrecur was within
the 95% isodose; or 3) ‘‘outside,” in which less than 20% of Vrecur
was within the 95% isodose.Table 1
Patient and treatment characteristics. KI, Karnofsky index; OTT, overall treatment time; A
S
Social status Single 2
Partner 5
Unknown 1
Age <70 8
>70 1
Gender M 7
F 2
KI performance status >80 7
<80 2
Unknown 1
Tumor site CUP 4
Larynx 1
Oral cavity 1
Hypopharynx 2
Oropharynx 4
HPV+ 7
HPV 3
Unknown 3
AJCC stage I 1
II 1
III 1
IV 6
T-stage x 4
1 1
2 3
3 3
4 2
N-stage x 1
0 2
1 1
2 5
3 3
Pretreatment dysphagia Grade 0 5
Grade 1 2
Grade 2 1
Grade 3 1
Neo-adjuvant chemotherapy No 9
Yes 5
Pretreatment lymph node dissection No 7
Yes 1
Prescribed dose (in Gy) for PTVther Mean 7
SD 1
OTT (days) Mean 4
SD 2
Planned dose reached Yes 9
No 2
Concurrent systemic treatment Platinum based 5
Targeted therapy 5
Other 1
No 3
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Patients
Between May 2008 and May 2011, 200 patients were included
and randomized. Treatment characteristics of 7 patients could
not be retrieved before close-out date of this analysis, yielding
193 patients for analysis (96 in the experimental arm and 97 in
control arm). Patient characteristics are depicted in Table 1.
The study included 83 patients with an oropharyngeal tumor;
41 in the 40 Gy and 42 in the 50 Gy arm. 17 patients (20,5%) of
these 83 patients had an HPV positive tumor; 60 patients (72,5%)
had an HPV negative tumor and 6 patients (7%) had an unknownJCC, American Joint Committee on Cancer.
tudy arm (n = 96) Control arm (n = 97) p-Value
(%) (%)
7 28 27 28 0.9
2 54 57 59
7 18 13 13
0 83 85 88 0.4
6 17 12 12
5 78 84 87 0.13
1 22 13 13
0 73 67 69 0.75
6 27 28 29
1 2 2
4 5 5 1
8 19 18 19
1 11 9 9
2 23 23 24
1 43 42 43
10 0.35
1 29
3
1 0 0 1
0 10 12 12
9 20 25 26
6 69 60 62
4 5 5 0.1
1 4 4
2 33 40 41
4 35 30 31
5 26 18 19
1 0 0 1
2 23 26 27
6 17 14 14
4 56 56 58
3 1 1
2 54 54 56 0.16
6 27 32 33
7 18 10 10
1 1 1
1 95 95 98 0.28
5 2 2
9 82 78 80 0.85
7 18 19 20
0 70 0.37
.6 1.9
5 45 0.2
.3 2.6
4 98 93 96 0.68
2 4 4
6 58 61 63 0.44
5 7 7
1 0 0
4 35 29 3
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4 Dose de-escalation to the elective neck in head and neck cancerHPV status. The summary of the result of the HPV assessment can
be found in Table 1.Toxicity
Following a chi square test, we observed a trend toward less
dysphagia at 6 months (p = 0.02) and at 24 months (p = 0.07) in
the 40 Gy group. The difference in grade 2 dysphagia at 6 months
stands out with 3.8% in the 40 Gy arm versus 20.8% in the 50 Gy
arm. However, when accounting for early drop-outs and deaths
using longitudinal analyses, no statistically significant differences
regarding dysphagia between both treatment groups could be
observed (Table 2). The interaction between visit and treatment
was found to be not significant (p = 0.80) and when removing the
interaction from the model, the odds ratio between 40 Gy and
50 Gy for observing a lower grade of dysphagia was in favor of
the 40 Gy group, however clearly not significant; 1.40 (95% confi-
dence interval 0.93 to 2.10, p = 0.11). Furthermore, regarding mod-
erate dysphagia (Pgrade1) or severe dysphagia (Pgrade 3), we did
not observe significant differences between both groups.Table 2
Prevalence of dysphagia at each time-point.
Dysphagia
Randomisation G 0 G 1
Month 6 40 Gy 48 (61.5%) 27 (34.6%)
50 Gy 37 (51.4%) 20 (27.8%)
Month 12 40 Gy 45 (67.2%) 14 (20.9%)
50 Gy 37 (56.9%) 18 (27.7%)
Month 18 40 Gy 39 (68.4%) 12 (21.0%)
50 Gy 33 (55.0%) 19 (31.7%)
Month 24 40 Gy 39 (73.6%) 12 (22.6%)
50 Gy 34 (63.0%) 12 (22.2%)
Using a GEE proportional odds model including treatment, visit and their interaction, the
the odds ratio between 40 Gy and 50 Gy for observing a lower grade toxicity was 1.40 (
Table 3
Prevalence of salivary gland toxicityP grade 1 and salivary gland toxicityP grade 3 at ea
Pgrade1 salivary
gland toxicity
Total
Month 6 40 Gy 55 (68.7%) 80
50 Gy 63 (86.3%) 73
Month 12 40 Gy 47 (71.2%) 66
50 Gy 53 (80.3%) 66
Month 18 40 Gy 37 (63.8%) 58
50 Gy 49 (81.7%) 60
Month 24 40 Gy 34 (63.0%) 54
50 Gy 35 (64.2%) 54
Using a GEE logistic regression model including treatment, visit and their interaction, th
the odds ratio between 40 Gy and 50 Gy for having no salivary gland toxicity was 1.88
Table 4
Overview of the estimated outcome of the study and 95% confidence interval and corresp
6 months 12 months
40 Gy arm 50 Gy arm 40 Gy arm
OS 92.6% (85–96.4) 95.7% (88.9–98.4) 82.7% (73.3–89.0)
DFS 83.0% (73.7–89.2) 85.0% (76.0–90.8) 70.0% (59.6–78.2)
LFR 4.3% (1.4–9.8) 3.2% (0.9–8.4) 10.7% (5.5–18.0)
RFR 7.4% (3.3–13.9) 2.2% (0.4–7.0) 11.8% (6.2–19.3)
LRFR 10.6% (5.4–17.8) 5.4% (2.0–11.3) 20.3% (12.8–29.1)
MR 4.3% (1.4–9.8) 9.8% (4.8–16.9) 6.4% (2.6–12.6)
For OS and DF, differences were assessed using a log-rank test. For LFR, RFR, LRFR and MR,
a competing risk.
OS: overall survival; DFS: disease-free survival; LFR: local failure rate; RFR: regional fail
Please cite this article in press as: Nevens D et al. Reduction of the dose of radio
randomized clinical trial. Effect on late toxicity and tumor control. Radiother OWe observed a lower incidence of any salivary gland toxicity
(Pgrade 1), at 6 and 18 months (p = 0.01 and p = 0.04, respectively)
in the 40 Gy arm (Table 3). This was confirmed by the longitudinal
analyses (p = 0.01 and 0.03, respectively). The interaction between
treatment and visit was found to be not significant (p = 0.14) and
when removing the interaction from the model, the odds ratio
between the 40 Gy group versus the 50 Gy group for having no
salivary gland toxicity was in favor of the 40 Gy arm; 1.88 (95%
CI 1.07 to 3.31, p = 0.03).
No significant difference between both groups was detected
regarding stiffness of the neck, salivary gland toxicity Pgrade 3,
skin problems and mucosal integrity.Outcome
Median follow-up was 34.2 months (range 2.2–79.0). We did
not observe significant differences in outcome and survival
between both groups at 6, 12, 18 and 24 months (Table 4).
After 2 years, estimated overall survival was similar in both
groups (72% and 73% in the 40 Gy and 50 Gy group, respectivelyG2 G3 Total P(GEE)
3 (3.8%) 0 78 0.06
15 (20.8%) 0 72
7 (10.4%) 1 (1.5%) 67 0.21
6 (9.2%) 4 (6.1%) 65
6 (10.5%) 0 57 0.16
8 (13.3%) 0 60
2 (3.8%) 0 53 0.15
6 (11.1%) 2 (3.7%) 54
interaction was found not significant (p = 0.8332). When dropped from the model,
95% confidence interval 0.93 to 2.10, p-value = 0.1088).
ch time-point.
P(GEE) Pgrade3 salivary
gland toxicity
Total P(GEE)
0.01 2 (2.5%) 80 0.7
3 (4.1%) 73
0.23 3 (4.5%) 66 1.0
2 (3.0%) 66
0.03 2 (3.4%) 58 1.0
2 (3.3%) 60
0.84 1 (1.8%) 54 1.0
0 (0.0%) 54
e interaction was found not significant (p = 0.1442). When dropped from the model,
(95% confidence interval 1.07 to 3.31, p-value = 0.0281).
onding p values.
24 months p value
50 Gy arm 40 Gy arm 50 Gy arm
85.7% (76.6–91.4) 72.0% (61.4–80.2) 73.2% (62.3–81.4) 0.73
69.9% (59.5–78.1) 57.9% (47.1–67.2) 65.3% (54.6–74.1) 0.41
8.7% (4.0–15.5) 14.1% (7.9–22.1) 14.4% (8.1–22.5) 0.99
5.5% (2.0–11.6) 13.0% (7.1–20.8) 5.5% (2.0–11.6) 0.08
10.8% (5.5–18.2) 23.7% (15.6–32.8) 15.4 (8.9–23.7) 0.14
17.4% (10.4–25.8) 13.4% (7.3–21.3) 18.5% (11.3–27.1) 0.25
differences between groups were assessed using Gray’s testing, considering death as
ure rate; LRFR: loco-regional failure rate; MR: metastatic recurrence.
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Table 5
Site of the regional recurrences.
Recurrence 40 Gy ARM 50 Gy ARM
GTV lymph node 6 5
PTV lymph node 1 0
Outside planning volume 2 0
PTV elective 2 1
PTV: Planning Target Volume.
GTV: Gross Tumor Volume.
D. Nevens et al. / Radiotherapy and Oncology xxx (2016) xxx–xxx 5(p = 0.73)). Furthermore no statistically significant difference was
found in the estimated disease free survival at 2 years (p = 0.41),
although a lower rate was observed in the 40 Gy group (58%) in
comparison with the rate in the 50 Gy group (65%).
We did not observe statistically significant differences in esti-
mated locoregional recurrence rates between both groups at 6,
12 and 24 months. However, after 2 years of follow-up, the cumu-
lative incidence of locoregional recurrence was higher (24%) in the
40 Gy arm when compared to the 50 Gy arm (15%) (p = 0.14). The
estimated local recurrence rate was 14% in both groups.
Regarding regional recurrences, we see a difference in esti-
mated risk between both groups, however not significant
(p = 0.08): 13% vs. 6% in the 40 Gy arm and 50 Gy arm at 2 years,
respectively (fig. 2). In total, 17 regional recurrences have been
observed during follow-up (Table 5). Three of seventeen (18%)
occurred in the PTV elective (2 in the 40 Gy arm and 1 in the
50 Gy arm) whereas 12 regional recurrences were located in the
high dose volume (11 in the GTV, 1 in the PTV). Two regional recur-
rences occurred outside the planning volume in the 40 Gy arm.
Of the 17 patients with regional recurrence, 6 underwent sal-
vage neck dissection. Palliative chemotherapy was started in 4
patients, as salvage neck dissection was not considered to be
advantageous because of synchronous metastases (n = 3) or an
irresectable relapse (n = 1). No further therapy was provided in 7
patients because these patients opted not to be treated.
Regarding estimated metastatic risk, we observed no significant
differences; however we observed a lower incidence (13.4%) in the
40 Gy arm when compared to the 50 Gy arm (18.5%) after 2 years
of follow up (p = 0.25) (fig. 3).Discussion
In this paper we describe the late toxicity and outcome of a
multicenter randomized controlled trial reducing the dose to the
elective lymph nodes in patients treated for head and neck cancer.R
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the most important quality of life compromising toxicity after
curative treatment of HNC [2]. Altered fractionation schedules,
concomitant chemotherapy and oropharyngeal tumor location
are associated with more dysphagia [6]. With the incidence of
oropharyngeal carcinoma in the western world on the rise, the
widespread use of concomitant chemoRT and the use of altered
fractionation schedules, prevention of late dysphagia will be of
upmost importance in optimizing the quality of life in these
patients [16–19].
Our preliminary analysis demonstrated that a dose de-
escalation to the elective lymph nodes, significantly reduced the
volume of the swallowing apparatus irradiated up to a high dose
without compromising target coverage and dose homogeneity.
Clinically this dose reduction resulted in significantly less grade
P3 dysphagia in the de-escalated arm 3 months after treatment
with similar LRC and DFS rates [12]. We also observed a better
quality of life in the 40 Gy arm (unpublished data, recently submit-
ted to Radiotherapy and Oncology).
The current updated results show a trend toward less late dys-
phagia, however not confirmed after longitudinal analysis. Further-
more, we observed significantly less moderate salivary gland
toxicity in the 40 Gy arm at 6 and 18 months, confirmed after lon-
gitudinal analysis. This is a somewhat unexpected finding, sincece End of Thearpy
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6 Dose de-escalation to the elective neck in head and neck cancerthere was no significant difference between doses tot the parotid
glands in both treatment arms, as published in our first paper.
No significant difference between both groups was detected
regarding stiffness of the neck, severe salivary gland toxicity, skin
problems and mucosal integrity. A possible explanation for this is
the fact that the high doses given to the PTV of the primary tumor
were identical in both groups.
Outcome in terms of local, regional and distant control and sur-
vival did not differ significantly between the groups after two years
of follow up. In the 40 Gy arm however, we observed a higher abso-
lute number of all regional recurrences (i.e. in the elective neck as
well as in pre-existing pathological lymph nodes). It was reassur-
ing that there were only 2 regional recurrences in the elective neck
outside the high-dose PTV in the 40 Gy arm and 1 in the 50 Gy arm.
Obviously, these numbers are too small to conclude that more elec-
tive neck recurrences would occur when lowering the dose in the
elective neck from 50 to 40 Gy NID2Gy.
It could be hypothesized that lowering the dose for subclinical
disease could result in less control and thereby in higher numbers
of distant metastases [20]. We did not observe more distant metas-
tases in the de-escalated group; on the contrary, a higher absolute
number of patients had distant metastases in the 50 Gy group (not
significant). This finding is reassuring with respect to the possibil-
ity to enhance occurrence of distant metastases when lowering the
dose to the elective neck.
So far, no randomized data on dose de-escalation to the elective
nodal volume in head and neck cancer were published. Therefore
the choice of 40 Gy for our de-escalation arm was quite arbitrarily
chosen, although supported by two non-randomized analyses
[21,22].
We hereby present the first study that demonstrates the non-
inferiority of dose de-escalation in the elective neck to 40 Gy in
terms of regional control in the elective neck. Meanwhile, a
follow-up multicenter trial has been conducted comparing dose
de-escalation in the elective neck using adaptive RT in reduced vol-
umes of the elective neck in an attempt to further diminishPlease cite this article in press as: Nevens D et al. Reduction of the dose of radio
randomized clinical trial. Effect on late toxicity and tumor control. Radiother Otreatment-induced toxicity. Combining data of both studies can
give us more information on the safety of dose-reduction to the
elective nodal volume.
Although the main purpose of the trial was to study the effect of
a dose-reduction to 40 Gy-equivalent dose in the elective neck, a
large heterogeneity remains between the treating centers in terms
of fractionation schedules, dose prescription to the high-dose PTV,
expansion margins from CTV to PTV, patient positioning protocols
and the use of concurrent chemotherapy. In order to avoid con-
founding effects of this center-dependent heterogeneity, the trial
randomization was performed per center.
Conclusions
Dose de-escalation to the elective nodal volume in HNC from a
50 to a 40 Gy-equivalent dose results in a trend toward less
dysphagia at 6 months and less moderate salivary gland toxicity
without significant differences in disease control or survival.
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